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Abstract: Research for the most selective drug delivery to tumors represents a fascinating key target
in science. Alongside the artificial delivery systems identified in the last decades (e.g., liposomes),
a family of natural extracellular vesicles (EVs) has gained increasing focus for their potential use
in delivering anticancer compounds. EVs are released by all cell types to mediate cell-to-cell
communication both at the paracrine and the systemic levels, suggesting a role for them as an
ideal nano-delivery system. Malignant pleural mesothelioma (MPM) stands out among currently
untreatable tumors, also due to the difficulties in achieving an early diagnosis. Thus, early diagnosis
and treatment of MPM are both unmet clinical needs. This review looks at indirect and direct evidence
that EVs may represent both a new tool for allowing an early diagnosis of MPM and a potential new
delivery system for more efficient therapeutic strategies. Since MPM is a relatively rare malignant
tumor and preclinical MPM models developed to date are very few and not reliable, this review
will report data obtained in other tumor types, suggesting the potential use of EVs in mesothelioma
patients as well.
Keywords: extracellular vesicles; exosomes; drug delivery systems; malignant pleural mesothelioma
1. Introduction
Cancer is a complex and multifactorial disease with both high incidence and mortality rates.
Approximately 1 out of 6 deaths are caused by cancer, making it the second leading cause of death
worldwide, with 9.6 million of deaths in 2018 [1]. Moreover, lung-associated cancers, with respectively
2.09 million worldwide cases and 1.76 million deaths in 2018 hold the primacy in terms of tumor-related
morbidity and mortality [1]. In recent years, a new multidirectional approach has been adopted in
oncology, by combining basic research aimed at enhancing our knowledge of the genetic and molecular
characteristics that drive tumorigenesis and tumor growth with the attempt to develop new molecular
targeting strategies for the treatment of pathology [2].
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Over the years, therapies targeting tumor pathologies have become increasingly pioneering,
in an attempt to overcome the limits imposed by classic chemotherapies, such as high toxicity,
poor specificity and, consequently, a plethora of side effects. Such an approach, which is increasingly
gaining ground, mainly concerns new delivery models and new therapeutic strategies that must be
as specific and selective as possible, taking full advantage of the genetic/biomolecular differences
of cancer cells compared to healthy tissues. Although survival rates have increased in recent years,
and promising clinical trials for targeted drug delivery are ongoing, current treatments for many
cancers remain ineffective and require the development of improved delivery methods. Indeed, in this
review, we highlight the current “target-therapy” strategies, focusing our attention on the strengths
and weaknesses of each approach. Moreover, we will focus on a particular tumor, the malignant
pleural mesothelioma (MPM). MPM is a tumor with a poor prognosis. The surgical approach has
significantly high perioperative mortality and high recurrence rate. In addition, chemotherapy is
frequently only a palliative treatment due to the onset of chemoresistance, characteristic of this tumor.
We therefore suggest the exploitation of extracellular vesicles (EVs) for the active delivery of therapeutic
molecules. In fact, the intrinsic molecular characteristics of EVs, such as the high editability and low
immunogenicity, make them the most suitable candidate. Currently there are no accessory therapies
for MPM to be implemented if the patient develops resistance or conventional therapies do not prove
effective. Therefore, since MPM has a “chameleon-like” extracellular profile that does not exhibit
specific markers to be exploited for selective targeting, it is difficult to diagnose promptly. In this
context, the use of a “Trojan horse”, self-produced by the tumor itself as a paracrine communication
mechanism, is a real possibility. In fact, we reiterate that none of the current therapies or the ongoing
clinical trials succeeds in what is the “unmet medical need”, that is, of therapeutic strategies aimed at
prolonging the overall survival of the affected population, whose current average is estimated between
4 and 18 months [3].
The concept of “targeted therapy” was born due to the insights of Paul Ehrlich at the end of the
1800s, when he first theorized the use of a “magic bullet” [4,5]. Even though the idea of combining
a cytotoxic molecule and a courier acting as a selective “bullet” was conceived for antimicrobial
application purposes [4–7], over time it has increasingly become suitable in the cancer field.
The strategies adopted in recent years in order to accomplish the expectations on targeted therapy
can be divided into two macro groups: on one hand, the first group involves the use of compounds
or antibodies, which can interfere directly with the biology of the cancerous tissue or the tumor
microenvironment; on the other, the second one concerns the developing of new drug delivery
strategies, which can improve the biodistribution on the tumor site. However, together with the
problems related to the best choice of a molecule to target in/on tumor cells, there are some issues
that were and are unfortunately disregarded in thinking about future cancer therapies. The first and
most important issue is related to the resistance of tumors to both chemical and biological treatments.
Initially, this was thought to be due to a mechanism called multidrug resistance, through which a
cancer cell is not responsive to most known drugs because of a group of proteins that are able to
pump the drugs outside the cells; the most studied among these proteins was the P glycoprotein-1.
This phenomenon of resistance of tumors to treatments has been described and characterized in several
in vitro models. The experimentation in tumor patients is ongoing and it is aimed to improve the
efficiency of anticancer drug delivery, overcoming the not responsiveness of tumor cells to conventional
therapy [8]. In patients with some forms of leukemia, the drug resistance has shown to be dependent on
the membrane-to-cytoskeleton connection through a family of proteins called ezrin/radixin/moesin [9].
This failure of scientific research seems to be due to the disregard of two important facts: (i) a
chemical drug enters within a cell due to a pH gradient and (ii) all solid tumors live in an acidic
microenvironment. In fact, being the vast majority of chemotherapeutics chemical drugs with an
electric charge, and being virtually all weak bases, when they get to the acidic tumor microenvironment,
they are protonated and therefore blocked outside the cells [8]. To support this finding, both buffers,
such as sodium bicarbonate, and antiacidic drugs could highly improve the antiproliferative effect of
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antitumor drugs [8,10]. Particularly, proton pump inhibitors have been shown to significantly improve
the effectiveness of antitumor drugs of different natures, including classical chemotherapeutics [11,12],
drugs targeting surrogate tumor molecules [13] and small molecules as well [14]. Some clinical trials
have supported the preclinical evidence [15–17], thus suggesting that this should represent at least one
of the future anticancer strategies.
In this review, we provide the current state-of-the-art of strategies in cancer targeted therapy,
with particular attention to EVs as new potential innovative nanocarriers with high targeting efficiency.
We summarize the current knowledge on EVs’ biogenesis and features, believing in the importance
of improving the understanding of their unique composition, in order to exploit them in clinical
applications. Furthermore, we focus on the MPM whose management could be implemented by the
application of EVs as a drug delivery strategy.
2. Strategies in Cancer Targeted Therapy
Patients’ response to treatments is related to the ability of the therapeutic system to be selective
and to reach only the target tissue without affecting healthy sites. In order to improve response
selectivity and to achieve a safer and more efficient systemic delivery, new technologies have been
developed. These strategies, in particular in the oncological field, need to include a system able to
release the active agent in a controlled manner and to target specific sites in the body, in order to
realize an interface between the patient and the drug and then increase the effectiveness and reduce
systemic effects.
Many new materials and approaches for drug delivery systems (DDS) are being developed.
Among these, EVs appear to be promising candidates as nanocarriers over the conventional synthetic
systems, considering their intrinsic features, including their tropism for specific organs or cells, their key
role in intercellular communication and their non-toxicity. The concept of drug delivery is rooted in
the early beginning of the 1950s. The first generation of DDS laid the groundwork of the controlled
release of compounds, but it was from the second generation of systems (1980–2010) that researchers
began to focus their attention on the setting up of smart DDS. Subsequently, from the third generation
of DDS (from 2010), researchers tried to overcome both biological and physiochemical barriers, such as
poor solubility of certain drugs, large molecular weight of protein-based drugs and the uncertain drug
release in some kinds of formulations [18].
Therefore, in the last ten years precision medicine and nanotechnologies gave a strong contribution
to the setting up of new delivery strategies, which may lead to a significant improvement of
biodistribution and biocompatibility.
2.1. Nanoparticles
In the context of safe and effective therapeutic approaches, nanoparticles have received extensive
interest as promising DDS for cancer treatment in recent years. Nanoparticles are the product of the
applied research of nanotechnology, which is trying to cross both physical and biological barriers of
the body in order to improve the drug delivery directly on the target site. In fact, when drugs are
encapsulated in structures that are larger than five nanometers, this can easily prevent renal excretion,
improving bioavailability [19].
Generally, nanoparticles can be defined as round nanospheres, built from synthesized
nanomaterials, ranging between 100 and 1000 nanometers [20]. As they are nanosized, the uptake
of nanostructures by cells is facilitated, allowing efficient drug delivery and ensuring target-specific
action [21,22]. A plethora of materials have been used in nanosized carriers for cancer therapy,
including polymers, lipids, protein–drug conjugates, viral nanoparticles, inorganic molecules and
metal nanoparticles [23,24] (Table 1). Nanoparticles offer great advantages in nanomedicine applications,
both in the diagnostic and therapeutic fields. In fact, the use of nano-systems is applied in early
diagnosis, through non-invasive imaging modalities, for instance, by the use of fluorescent or magnetic
systems. In the therapeutic field, research is trying to exploit their capability to trap, protect and deliver
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drugs to the target site, due to highly specific binding and internalization capabilities. Furthermore, it is
possible to synthesize nanoparticles that have the possibility to integrate diagnostic and therapeutic
entities within a single formulation, thus obtaining a single system capable of simultaneously satisfying
the criteria of theranostic approaches and providing real-time feedback on pharmacokinetics, including
the drugs’ target site localization and the off-target accumulation. These features are achieved due
to both the co-loading of nanoparticles with drugs and with contrast agents, and the intrinsic ability
of nanomaterials, such as gold and iron oxide-based nanoparticles, to be suitable to be used for the
imaging [25,26].
However, it is important to underline that the use of some materials can be potentially risky
for patients’ health [27]. In fact, carbon nanotubes, metal-based nanoparticles or even polymeric
nanoparticles have been widely investigated and used for possible clinical applications. Despite the
versatility of these therapeutic nanoscale agents used for the synthesis of nanomedicines, there are
potential adverse side effects induced by the materials used [27]. In this regard, “green chemistry”
approaches are increasingly considered in order to identify biocompatible/biodegradable nanomaterials
capable of eliminating the toxicological impact and potential side effects deriving from some materials
used, such as carbon nanotubes, metal nanoparticles or polymeric nanoparticles [27,28] (Table 1).
2.1.1. Liposomes
Liposomes are lipid-based nanoparticles and were the nanoparticles used in nanomedicine [29].
They consist of a single or multiple lipid bilayer that is engineered to encapsulate, in the lipid
bilayer or in the internal aqueous phase, hydrophobic or hydrophilic drugs or small molecules,
depending on their polarity features [30]. Liposomes are the most investigated nanocarriers for
targeted drug delivery, because of their morphological similarity with cellular membranes, allowing
biocompatibility and minimal toxicity [31]. Furthermore, due to the possibility to modify their lipid
bilayer characteristics and to build a large aqueous center, these nanoparticles permit to deliver a
wide variety of macromolecules [32]. There are different classes of liposomes used as drug delivery
systems, which are classified on the basis of size and number of layers; based on the composition,
and on the method of preparation [33]. Moreover, in the last few years new liposome formulations
have emerged, which are stimulus-sensitive and offer a more efficient drug release [34]. In a wide
range of pathologies, liposomes seem to be effective as a target-therapy approach; indeed, it has
been observed that they are able to improve and control pharmacokinetics and pharmacodynamics,
to enhance drug activity, and are target selective. In cancer therapy, the use of liposomes offers several
advantages, including efficient internalization by cancer cells that exploits the passive targeting effect,
a phenomenon known as enhanced permeability and retention [35]. The in vitro and in vivo delivery
efficacy of different liposomes formulations has been extensively studied in anticancer therapy and
several data demonstrated low systemic toxicity and the capability to suppress tumor growth [36–39].
Despite the potential use of liposomes in the area of drug delivery, clinical applications have so
far been negligible. In fact, there are some disadvantages limiting the development of liposome-based
therapies, such as sensitivity to sterilization methods [40], stability issues [41], reproducibility in drug
encapsulation, particle size control [42], short shelf-life and stability in blood circulation [43] (Table 1).
Int. J. Mol. Sci. 2020, 21, 5432 5 of 29
Table 1. The advantages and disadvantages of main drug delivery approaches. Abbreviations: ADC, antibody-drug conjugated; EVs, extracellular vesicles.
Strategy Advantages Disadvantages References
Nanoparticles
• Flexibility
• High stability in vivo
• Increased compound half-life
• Hydrophilic and lipophilic compounds can be both loaded
• Enhanced permeability of tumor vasculature facilitates
nanoparticle delivery on the tumor site
• Depends on the nanoparticle type
• Inorganic nanoparticles may trigger the immune-system [19–28]
Liposomes
• Similarity with cell membrane
• High variety of drug encapsulation
• Low systemic toxicity
• Sensitivity to sterilization methods
• Low stability in circulation




• Increased compound half-life
• Increased high-dose drug tolerance
• Increased specificity
• Deep knowledge of polymer–receptor molecular interactions
required




• Various anticancer effects
• High cell permeability
• Low systemic toxicity




ADC • High specificity• Remarkable results for AB working as single entities
• May trigger the immune system
• High production costs
• Some clinical trials showed no significant improvement of
patient outcomes compared to canonical therapies
[4,70–78]
Reconfigurable Organisms
• Extremely configurable organisms
• High drug loading efficiency
• Autonomous, self-repairing system
• Machine learning is still unripe
• Research in this field is still in the embryonic stage [79]
EVs
• High biocompatibility due to the endogenous origin
• High specificity
• Can be highly modified in order to enhance or modify
tissue specificity
• Due to the phospholipid bilayer, they can easily fuse directly
to the target’s plasma membrane
• Presence of specific surface markers that preserve them
from phagocytosis
• Functional complexity, not easy to artificially replicate
• Generally low efficiency of EVs isolation methods
• Lack of clinical evaluations
• Lack of standardized isolation methods
• Deepening of the understanding of intracellular
production/packaging mechanisms still ongoing
[80–152]
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2.1.2. Polymer-Conjugated Drugs for Selective Delivery
Ringsdorf properly described the concept of polymers and biopolymers-conjugated drugs in
1975 [44]. Water-soluble polymers are an efficient drug delivery system that can highly increase the
half-life of compounds, significantly improve the general tolerance to high doses of drugs (such as
chemotherapeutic drugs) and implement specificity. The first example reported in the literature
of polymer-conjugated drugs is the dextran-methotrexate conjugate [45]. Kidney excretion of the
chemotherapeutic drug was prevented, improving also the drug’s circulation in the blood stream.
There are plenty of examples of peptides used as drug delivery vectors, which show promising
results. Among these, the multiple antigen peptides (MAP) are one of them as they have both the
specificity of an antibody and the versatility of a peptide. The branched structure of MAP peptides was
originally designed to be used in the vaccination field [46,47]. However, in recent years the multimeric
bond has been further analyzed in order to implement the avidity of the molecule. In fact, despite
having a short amino acidic sequence and being in a branched form, it still was not able to trigger an
effective immune response; the same cannot be said for the property of these molecules in terms of
avidity and specificity. Therefore, if supported by a solid affinity and interaction study, target-peptide
could become a reliable drug delivery model.
In this regard, an example could be the NT4, a tetra-branched form of neurotensin, which in the
MAP form is correlated to a high affinity for the sulphate groups present in the glycosaminoglycans
(GAGs) chains, highly expressed in most solid tumors [48–50].
It is possible to combine different chemotherapeutic drugs to the tetra-branched core of NT4,
exponentially increasing their selectivity [48,51], as drug delivery to the target is strictly related to the
carrier and with how much specificity it binds to its receptor (Table 1).
Progress achieved in recent years has made it possible to better implement and structure the
NT4-based delivery system. In fact, the tetra branched peptide conjugated with the chemotherapy
compound paclitaxel (PTX) was compared in an in vitro study with the PTX counterpart in the
unconjugated form, demonstrating how the NT4-PTX complex can induce tumor regression, while the
free PTX just led to a slowing down of tumor proliferation [51]. The delivery system was then refined
and implemented, conjugating the NT4 peptide with NIR-emitting quantum dots nanoparticles (QD).
The two tested formulations, NT4-QD and NT4-QD-PTX, have demonstrated effectiveness in vitro
both in diagnosis/identification of the tumor itself and in theranostics on HT-29 cells, showing a higher
cytotoxicity compared to the QD-PTX control-formulation used [52].
There are many possible applications of MAP peptides, including practical applications in the
diagnosis of solid tumors [53]. However, practical applications are not limited to the oncological field:
the properties of the multimeric bond are in fact provided by a huge variety of clinical contexts, such as
in the implementation of the half-life of antibody fragments (Fab) injected intravitreally [54].
In this regard, the research group of Whitney Shatz et al., starting from a polyethylene glycol
structure (PEG) backbone, synthetized an octameric Fab-PEG structure, capable of being administered
intravitreally in order to treat age-related blindness pathologies. [54].
2.2. Small Molecules, Peptides and Antibody in Targeted Therapy
Small molecules are compounds whose molecular weight is generally <900 Daltons. Due to their
small size, they can easily diffuse inside the cells, bind specific targets and expound their therapeutic
function [55]. Small molecules in cancer carry out their function in different ways, such as intruding on
the cell cycle, triggering apoptotic signals, and interfering with key enzymes, crucial for cell metabolism
and slowing down tumor invasion and metastasis. Those molecules can also interfere with the tumor
microenvironment, blocking the angiogenesis, boosting or regulating the immune system [56,57].
An analogue function is absolved by the monoclonal antibodies (mABs), largely used in clinics
for a great variety of tumoral conditions. Those antibodies are developed starting from the hybridoma
technology [58] and have been used in clinical trials since the 1980s [59]. MABs are usually produced
for extracellular targets, and can fulfill their therapeutic function in both a direct and an indirect
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way. In the first case, the antibody is produced to recognize specific structures exposed on the tumor
extracellular membrane, such as growth factor receptors or membrane bound proteins [60].
In the second case, mAB can be useful tools for the handling of tumor microenvironment, i.e.,
interrupting the interactions between ligands and their receptors (EGF, endothelial growth factor;
vascular endothelial growth factor, VEGF; etc.), or promoting the recruitment of the immune system,
in order to facilitate a direct and specific attack to cancerous cells.
Antibody-based therapy has deep roots in the history of biotechnologies. In fact, starting from
serotherapy institutes (such as The Institute of Serotherapy and Vaccination of Tuscany), where active
immunization against specific antigens was induced in large animals, such as horses, in order to use
their plasma as a medical tool, subsequently we finally reached a more sophisticated biotechnological
product [4,61].
The production of monoclonal antibodies originated in the early 1970s. Due to the two researchers
Georges Kohler and Ceasar Milstein, the massive production of mABs was assessed using the hybridoma
technology. The technology developed by the two researchers was never patented and it might be
considered as a milestone in the large-scale production of mABs for therapeutic purposes. Therefore,
due to the hybridoma technology, it was possible to produce and market the first murine mAB in 1986,
“muromonab-CD3”, a full mouse mAB used to prevent kidney transplant rejection [62–64].
However, the clinical use of full murine antibodies has several limitations. The murine structure
of the antibody might be recognized as “not self” from the patient, which may lead to a consistent
immune reaction against the injected mAB.
Technological evolution and knowledge acquired in the field of genetic engineering have
subsequently allowed one to create antibodies made of both murine genetic sequences and human
genetic inserts, in a ratio of 33%–66%. Essentially these antibodies, which were defined as “chimeric”,
presented a human Fc fragment, and a murine Fab. Antibodies thus constituted were less immunogenic
than the murine counterpart was. The first chimeric antibody with these characteristics was approved
for antithrombotic therapy in 1994, with the commercial name of Reopro® (Abciximab) [4,64].
With the refinement of technology, it was possible to obtain chimeric antibodies containing less
and less murine DNA, up to the so-called humanized antibodies consisting of 90–95% of human DNA
sequences. In this typology of antibodies, the murine regions were located mostly in correspondence
of the complementary-determining regions (CDRs). The first humanized antibody approved by the
FDA in 1997, to prevent rejection following kidney transplants, was Zenapax® (Daclizumab) [4,64].
Another important step forward in the production of mAB has been made through the introduction
of the phage display technique. This technique allows the study of protein–protein interactions, starting
from the genetic sequence of interest inserted within a viral vector, generally the bacteriophage M13.
This protein of interest is exposed on the outer shape of the phage, preserving the genetic sequence of
the interest inside. These phages are then subjected to interaction screening with the target protein,
making possible large-scale affinity screening starting from genetic libraries, consisting of variants of
the gene of interest [4,64,65].
Later in 2006, due to the phage display technology, it was possible to produce and market the first
completely human monoclonal antibody, Humira® (Adalimumab). The fully human antibody structure
(100% compared to 90–95% of humanized ones) takes a step forward in the field of immunological
therapy: murine CDR of humanized antibodies has been replaced by fully human CDRs, so that
Adalimumab effectively improved compatibility and avoided structure-related immunogenicity.
The applications of mAB are various and can be used as powerful drug-carriers. Antibody-drug
conjugates (ADC) are interesting tools in precision medicine, in which the mAB is covalently linked
with a cytotoxic compound in order to be driven directly on the tumor site [60,66–68]. Of course,
the above issue of acidity-mediated drug resistance still stands in the case of more targeted or smaller
molecules, but for biological compounds as well, inasmuch as it appears highly conceivable that the
acidic microenvironment may well hamper the affinity of a mAB for its specific epitope. Moreover,
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recent evidence has shown that microenvironmental pH markedly changes the lipid composition of
tumor cells, thus hampering the hypothetical binding between a ligand and its receptor [69] (Table 1).
2.3. ADC
The therapeutic potential of antibodies has been deepened between the late 1800s and the early
1900s, when horses and oxen were exposed to an antigen in order to produce specific antibodies to it.
Despite the remarkable risk of rejection that the administration of animal immunoglobulins entailed,
it is undeniable that such a practice has helped to encourage future studies and biotechnological
innovations related to the engineering of antibodies for therapeutic purposes. Additionally, in the
oncological field, the therapeutic applications of antibodies are several, as they can act as single
entities, conjugated with a drug or an enzyme that in turn is capable of activating a drug, administered
systemically [4]. There are several examples of antibodies that work as single entities, targeting a
specific aberrant or overexpressed receptor component in neoplasms. An example may be Herceptin®,
a humanized mAB for the treatment of metastatic breast cancer: it exerts its function binding the
tyrosine-kinase receptor HER-2 present on the cell membrane.
Another example could be AVASTIN® (Bevacizumab), a mAB aimed at the VEGF-A, proangiogenic
growth factor. In combination with chemotherapy, it is approved for the treatment of advanced colorectal
cancer, advanced non-small cell lung cancer and metastatic breast cancer [70–72].
Besides working as independent entities, several mABs exert their function conjugated with
chemotherapeutic drugs or with radioactive ligands [73,74]. Indeed, numerous antibody-drug
conjugates have been developed for the selective delivery of chemotherapeutic agents, and many of
them have been tested in clinical trials; however, for some of them there was no significant improvement
of the patient’s outcomes, compared to classical therapies [75–78] (Table 1).
2.4. Reconfigurable Organisms as Drug Carriers
A new promising study driven by the team of S. Kriegman et al. [79] opens up to a new way of
conceiving nanomachines and, by extension, drug delivery. The research group focused its studies
on a completely innovative model, which, starting from different biological tissues originating from
Xenopus laevis embryos, gives rise to biological machines from scratch. Using compiler algorithms,
3D structures have been designed by the computer whose “blocks” are constituted by the epithelial
and cardiac cells of the frog embryo. The most promising models are thus selected and used through
the help of high precision manipulators, following the model path suggested by the computer.
These “Xenobots”, thus defined by the research group, have several interesting peculiarities, including
the ability to automatically self-repair, preserving their own integrity. The high motility is conferred
by the cardiomyocytes content because the embedded cardiac cells make the structure self-propelled
and establish a predictable path a priori. These structures, although still being in the early stages
of research, have enormous potential, especially in the “drug delivery”, as they allow following a
pre-established path and managing a load within the core [79] (Table 1).
3. EVs
EVs have recently entered solid tumor research, regarding the new possible targeted drug delivery
systems, offering considerable advantages due to their intrinsic characteristics. Given this, and as the
EVs are the object of our study, we devote a separate section for their discussion in this review.
EVs are lipid membrane vesicles actively secreted by all human cells and are involved in a plethora
of cell-to-cell communication processes, both in pathological and physiological conditions. Although
they were thought to be “garbage disposals” that eliminate unwanted cellular components, such as
misfolded proteins or metabolic wastes [80,81], decades of research have defined their pivotal role in
coagulation, cell-to-cell communication (both paracrine and systemic levels), vascular injuries and,
more in general, in cellular maintenance of homeostasis [82].
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EVs are actively secreted from all cell types, including cancer cells, and are highly heterogeneous
in size, lipid layer composition and cargo (such as nucleic acids, proteins and lipids). In addition,
EVs are classified according to their size: (1) microvesicles (100–1000 nm in diameter); (2) apoptotic
blebs (1000–5000 nm in diameter) and (3) exosomes (diameter 20–150 nm). On one hand, the first two
subclasses: they are a wide and heterogeneous population of vesicles originated from the outward
budding of the cell membrane. On the other side, exosomes follow a different path, originating from
the invagination of endosomal membranes. This invagination gives rise to multivesicular bodies
defined by the presence of intraluminal vesicles (ILVs). The endosomal sorting complex required
for transport (ESCRT) complex family mediates the inward folding of the membrane of the early
endosomes, resulting in ILVs formation into the lumen [83–86]. The ESCRT is composed of four
distinct proteins (ESCRT-0, -I, -II and -III), that accurately regulate biogenesis and cargo loading into the
exosomes [87]. It is hypothesized that different structures for sorting molecules from cytoplasm toward
exosomes may depend on their source cell. Additionally, the function of the cells can be understood
via their released EV content [88].
Due to the heterogeneity existing within the EVs family, where boundaries between the various
groups are often not easily distinguishable, a distinction is still problematic since the characteristics
of these membranous vesicles overlap with each other, so in this review, we refer to EVs and
exosomes commonly.
However, a specific type of EVs might be more represented rather than others, depending on
the isolation method used. The EVs isolation methods development represents one of the greatest
challenges in the case of the exploitation of EVs as therapeutic tools. Owing to the fact that the isolation
protocol should achieve high efficiency, high purity and reproducibility. Among them, the gold
standard in EVs isolation methods is represented by the differential ultracentrifugation, based on
isolation by size. Over the years alternative methods have been developed, based on the size and the
hydrodynamic radius, such as ultrafiltration, hydrostatic dialysis and gel filtration. Other approaches
are precipitation methods, which exploit the variation of EVs solubility and/or their aggregation when
placed in polymeric solutions, and lastly, methods utilizing affinity interactions, such as immunoaffinity
techniques. Further information on technical issues on the isolation methods of EVs can be found in
recent papers [89–92].
Each of these methods has its own advantages and weakness and the choice should be based on the
sample type from which isolate EVs and depending on the final application. Nevertheless, due to the
complexity of biological fluids from which EVs are being isolated, all the methods developed allow one
to obtain heterogeneous mixtures of EVs and other extracellular space components. One solution may
be the use of multiple isolation methods consecutively, in order to enrich a particular EVs population.
Since the EV isolation efficiency is dependent on the nature of biological fluids, it is most important to
standardize a particular method for isolation of EVs, taking into account specific characteristics of the
sample, such as viscosity, typical of blood plasma and serum and, the presence of specific proteins,
e.g., THP in the urine. Besides, the characterization of the obtained EV preparations, through the
combination of different methods, such as electron microscopy, light scattering, flow cytometry and
immunohistochemical analysis for the markers specific, is recommended to confirm the EV morphology,
physical features and biochemical composition [83].
Exosomes are the main type studied among the family of EVs. They mediate the cell communication,
and can be found in a large spectra of body fluids, such as blood, seminal fluid, urine, saliva, breast milk,
ascitic fluid, bronchoalveolar lavage, malignant effusions, cerebrospinal fluid and amniotic fluid [88,93,94].
The intravesicular cargo may variate depending on the cell type that secretes them and according
to their specific function on the recipient cell, such as cytokines [95], hormones [96], transcription
factors, growth factors [97] and heat shock proteins [98–107]. Moreover, there is a large number of
proteins that compose the structure of exosomes, which are directly involved in cell trafficking and
their specificity: exosomes are enriched in proteins involved in the vesicles’ trafficking, cell surface
receptors such as tumor susceptibility gene 101 (TSG101); integrin and a number of tetraspanins such
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as CD9, CD53, CD63, CD81 and CD82 [108,109]. Tetraspanin proteins are a functional ubiquitous
region in the endosomal membrane, which assist in sorting of the cytosolic component into ILVs [110].
The release of EVs by tumor cells is believed to play a major role in intercellular communication,
facilitating signaling to surrounding tumor cells and to distant sites via blood or other biological fluid
transportation. Indeed, EVs cancerous cells can communicate with other tumor cells, with fibroblasts
that surround the tumor, with endothelial cells and inflammatory cells, such as monocytes or T-cells [83].
As concerns fibroblasts, under tumorigenic conditions, they can be induced to change their
morphological features, promoting a myofibroblast-like phenotype, more motile than the normal
fibroblasts that surround the tumoral stroma. It has been proved that through the active secretion of
EVs, tumoral cells can drive the polarization of normal fibroblasts into activated cancer-associated
fibroblasts [111–114].
Strong evidence also underlines the EVs’ involvement in the angiogenesis in a plethora of tumor
types [111,115–118]. The angiogenic activity is flanked by a pivotal role in the promotion of cell
migration and metastasis in many tumor types [115], and the main mediators of this activity seem to
be miR-9, miR-105, miR-142-3p, miR-210, miR-19a and H19 lncRNA [100,119–123].
For what may concern the immunomodulation, the literature has plenty of discordant results,
which reflect the heterogeneity of EVs and their cell-specific function. Zhou M. and his research group
show how pancreatic derived EVs mediated the expression of Toll-like receptor 4 (TLR4) in dendritic
cells, promoting an antitumor immune response [86]. This strong evidence, taking in account the
presence of major histocompatibility complexes on the surface of EVs that are also able to display
cancer-derived peptides, suggested the possibility to develop an EV-based anticancer vaccine [124,125].
Despite those promising results, other evidence underlines how EVs have an inhibitory effect on
immunomodulatory cells, especially on macrophages and dendritic cells [126,127].
Considering all the above, the possible therapeutic use of EVs in clinics becomes clear.
Exosomes might be used as possible therapeutic targets in cancer, due to their confirmed role in
tumorigenic progression, cancer cell communication and metastasis. In triple negative breast cancer
(TNBC), for example, it has been proved that exosomes are involved in both the promotion of drug
resistance and in the transferring of phenotypic traits from a progenitor cancer cell to another cell,
thusly promoting cancer progression and metastasis [115]. The inhibition of exosome production in
TNBC has been deepened through the blocking of ESCRT-independent pathways, or silencing the
Rab27, which mediate another exosome-production pathway: in both cases, experimental evidence
shows a slowing down of cell proliferation rate and reduction of local growth and metastasis [128,129].
Nevertheless, mostly and coherently with the aim of this review, exosomes might be a great
potential drug delivery system [130,131]. Differently from what we have seen with the other
abovementioned delivery systems, which in a few cases turned out to be poor in efficiency and
high in immunogenicity and general tolerance [132], the endogenous origin of exosomes gives them a
“boost” in terms of low immunogenicity and high specificity [115,133,134]. The intrinsic specificity of
cancer-associated exosomes, which, as mentioned before, are the main characters in cancer cell-to-cell
communication, make them powerful tools in the cancer-drug delivery system. Moreover, exosomes
can be highly modified in order to enhance or modify their tissue-specificity, widening the amount of
feasible therapeutic strategies [135]. Notably, preclinical studies have shown that exosomes are able
to shuttle different kinds of molecules, including chemotherapeutics [136], drugs possibly useful to
work as both effective molecules and tracers, representing a prototype for “Theranostics” [137,138],
but nanoparticles as well [139], thus really supporting their exploitation as a natural delivery system
for both diagnostics and therapeutics [140,141]. Moreover, their structure allows them to deliver active
molecules as well, and this has been shown in in vitro models [142], and in vivo as well [143]. Lastly,
it has been shown that exosome release and size are profoundly changed by extracellular acidity [144],
suggesting that when using EVs or exosomes as a delivery system for the treatment of cancers the
source of these should always be chosen very carefully [7] (Table 1).
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EV Bioengineering and Drug Loading
To consider developing EV-based therapy, it is necessary to take into account the cellular source
from which to obtain them. Actually, although it is known that all cells can produce EVs, they should
have some physical and biochemical characteristics that make them suitable as drug carriers. Among
them, several features have been investigated, such as composition, influencing immunogenicity and
targeting; loading capability, which affects therapeutic efficiency [145].
Currently, mesenchymal stem cell-derived EVs (MSC-EVs) are being studied and many
experimental data have confirmed that these vesicles mimic the immune-regulating function and
regenerative capacity of MSCs. The therapeutic potential of MSC-EVs, which exploit some intrinsic
EV features, has been found in preclinical studies in various tissues, e.g., nervous tissue, cartilage
and bone [146–149]. The mechanism of action of this type of EVs includes the activation of the
immune system and the promotion of injury healing. In addition to the MSC-EVs, EVs from cells
such as embryonic stem cells, induced pluripotent stem cells [150] and cardiomyocytes [151] have
good therapeutic potential. In addition, dendritic cells have been used as EV cell sources in therapy,
since they preserve the immunostimulatory functions of parental cells [152] and are able to cross
biological barriers [153] with minor side effects [154]. Similar anticancer effects have been demonstrated
for macrophage-derived EVs that modulate an immune response, including cell-mediated response
against cancer cell growth [155,156]. Nevertheless, the role of macrophage-derived EVs appears
ambiguous and it has been observed that they can favor both antitumoral and tumoral immune system
stimulations [157].
As stated above, EVs, being carriers of natural active molecules including lipids, proteins, nucleic
acids and other metabolites, have a broad therapeutic potential per se. However, for therapeutic
applications, EVs should be obtained in significant amounts. Certainly, the achievement of clinically
relevant doses highly influences EVs based therapy. Obtaining a sufficient quantity of EVs for clinical
applications is influenced not only by the source, but also by the isolation processes and by the sample
preservation and manipulation. Furthermore, these methods must ensure a high degree of quality,
safety and consistency mandatory for clinical applications [158].
Although cell culture-derived EVs have been mainly used, other types of EVs can be easily isolated
and manipulated, both in direct and indirect ways, to carry and deliver therapeutic molecules.
A possible approach consists of the isolation and engineering of cells from the patient, starting
from body fluids [139,159] or from various foods including milk, fruits and vegetables [160,161].
Therapeutic compounds can be loaded within these EVs and infused into the patient.
The efficiency of this strategy is dependent on the kind of biological sample. Among the body
fluids, blood plasma represents the most investigated EVs-source, both as a diagnostic tool (through a
low invasive liquid biopsy) and as EVs producing cells reservoir. This because of the low invasiveness in
obtaining it and because it contains cells that can be isolated and expanded in vitro for EVs production,
and also because it contains a large amount of EVs produced by all the cells of our body and potentially
shed into the bloodstream. For instance, monocyte-derived macrophages present in the blood have
been shown to represent a safe and valuable source for therapeutic exosomes [162], and platelet-derived
EVs that are rich in growth factors and noncoding RNAs [163,164]. These evidences support the idea
that blood constitutes an almost ideal “EVs-source reservoir”, compared with other bodily fluids,
for the production and isolation of clinical-grade EVs [158] both in terms of large-scale production and
clinical feasibility [165].
Regarding EVs purified from foods, such as plant-derived or milk-derived EVs, despite that they
can offer an easy and large-scale production and result particularly stable, may raise different concerns
than human source-based therapeutics EVs. It has been shown that food-derived EVs are carriers of
toxins and allergens that may determine immune reactions [166–168] (Figure 1).
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candidates in the treatment of nu rous pathol gies and th re are various reliable sourc s. EVs can
be isolated from the cell culture s pernatant of various producing cell lines, from body fluids and
also from food. (2) The EVs molecular composition is complex and it depends on the cellular source.
They can contain different classes of proteins (membrane-bound tetraspanins CD9, CD81 and CD63;
receptors, heat shock proteins), ncRNAs (RNAs; MicroRNAs) and lipids (lysobisphosphatidic acid;
phosphatidylcholine; phosphatidylethanolamine and sphingomyelin). (3) The different methods to
manipulate the EVs content include the preloading approach, in which a pre-existing endogenous cargo
is the therapeutic molecule. In the display technology, the EV-producing cells can be engineered with a
plasmid in order to induce the expression of exogenous proteins. The post-loading method consists in
the direct introduction of drug molecules into EVs after their isolation. (4) The engineered EVs may
also be manipulated to be more bioactive and bioavailable and can be administered to patients for the
MPM therapy.
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Bioengineering applied to EVs is a tool used in order to induce EVs to uptake an exogenous cargo,
and to drive it into specific body districts for therapeutic purposes (Table 1).
Actually, there are two main different approaches to manipulate EVs: a pre and a post-loading
method. These two are technically and theoretically different. The pre-loading approach consists of
using a pre-existing endogenous cargo as the therapeutic molecule [169] (Figure 1).
The pre-loading method is the easiest way to obtain therapeutic EVs, because the potential
therapeutic molecule is already inside the vesicles. One of the main issues of this methodology is
the impossibility to control the amount of cargo loaded into the EVs. If it is true that endogenous
molecules, such as miRNA, have a high potential in therapeutic purposes, it is also true that for nucleic
acids natural EV content is very poor [170–172] (Figure 1).
Therefore, it is clear that a deeper understanding of the sorting mechanisms that regulate the
miRNA and other nucleic acids loaded into the EVs is very important: several research groups are
trying to clarify this process, indicating for example Annexin A2 and Y-box binding protein 1 (also called
as nuclease-sensitive element-binding protein 1) as two coworkers able to bind miRNA sequences
mediating their EV’s loading (the first one in a sequence independent manner and the second one
related with the binding with miRNA-223) [171,173,174].
These modifications made on EV-producing cells can be various and are somewhere between
a “pre loading” and a “post loading” method. In fact, through genetic engineering techniques, it is
possible to induce an overexpression of therapeutic molecules, such as miRNA, siRNA or proteins
on the producing cell [171,175] (Figure 1). The fusion of therapeutic proteins with EV’s localized
proteins is an efficient strategy that might drive the expression of the interest protein onto the EVs
surface: this specific technique is called “Exosome display technology” [175,176]. Another promising
approach is the use of specific functionalized domains in order to induce the expression of exogenous
proteins: for this purpose the constant region one and two (C1C2 domain) of Milk Fat Globule-EGF
Factor 8 Protein (also called Lactaderin) might be used, and promising works show the efficacy of this
technique [171,176,177] (Figure 1).
The post-loading method consists of the encapsulation of therapeutic molecules on the EVs after
their isolation. It is more efficient than the pre-loading one, because manipulating EV’s cargo after
the isolation gives the operator a deeper control on the encapsulation efficiency (EE%) and loading
capacity (LC%) of the final product. Those two are parameters used to calculate the efficiency of the
final product in DDS [178,179], according to the following equations:
EE% =
Molecules correctly encapsulated with the drug
Total amount o f molecules
× 100 (1)
LC% =
Molecules correctly encapsulated with the drug
Amount o f carrier that carries drug (EVs in this case)
× 100 (2)
It is possible to intervene on EVs cargo through three different ways: chemical-treating EVs,
through physical methods or using electroporation (Figure 1).
Sometimes the lipid bilayer prevents passive encapsulation of therapeutic compounds, so using
chemical solvents in order to create pores on the lipid surface, or using some freezing–thawing cycles,
can facilitate the drug loading into EVs [180,181]. In reality, the gold standard for the manipulation
of EVs is electroporation: the electric pulse can induce the formation of pores on the surface of the
vesicles, allowing migration of therapeutic compounds into them [177]. However, electroporation and
approaches that affect EVs membrane stability and integrity present limitations due to the creation of
aggregates, leading to an overestimation of the loading efficiency [135,182].
In cancer therapy, there are several examples of EVs encapsulated with chemotherapeutic drugs,
such as doxorubicin or patitaxel, which are currently ongoing on preclinical trials [183,184].
It is important to underline how the choosing of bioengineering methods is strictly related with
the properties of each compound used.
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The possibility of exploitation of EVs as therapeutic nanocarriers has entered the field of anticancer
therapy in the last decade, due to the similitude with liposomes, which have been studied for a long
time for their capability to encapsulate drugs. Considering some physical features and the structure
of the lipid envelope, EVs and liposomes appear similar [185]. Moreover, it is possible to synthesize
liposomes so that they share many of the membrane properties of exosomes [186,187]. Despite this,
although several liposome-based drug products are currently available in the market [188], they lack in
selectivity and they can induce side effects, so much so that the clinical trials of liposomes turned out
to be poorly effective [188]. Compared to liposomes, EVs have a unique lipid and protein composition,
which favors targeting and organotropism. In fact, as mentioned above, EVs play a key role in
cross-talking between cells and, due to the biogenesis mechanism, they have a very similar membrane
to the cells that produced them; consequently, this would represent a characteristic to be exploited,
for example in autologous therapy, to reduce renal clearance. In addition, immune compatibility, due to
the EVs’ membrane features, constitutes an advantage that establishes them as a suitable target-therapy
strategy, when compared with liposomes. Similarly, to liposomes, when injected intravenously EVs
are rapidly cleared by the reticuloendothelial system in the liver and spleen, reducing drug efficacy.
On the contrary, exosomes administered in a tumor in situ have a major rate of association to cancer
cells and besides, autologous EVs show an enhanced organotropism [189]. In terms of immune
compatibility between the EVs donor and receiving host, the allogeneic EVs applications seem to be
feasible, for instance, taking into account the typical practices in hematopoietic transplantation (HLA,
human leukocyte antigens-matching) [165,190–192]. Currently, strong evidence that can demonstrate
the immune effects in allogeneic administration of EVs is lacking. Thus, the complete characterization
of EVs and the source of EVs may lead to a robust definition of the mechanisms underlying the
therapeutic effect of EVs [169].
The intrinsic ability of EVs to bind target cells, as mentioned before, is a particular point on
targeted therapy. However, it is also possible to think to improve this natural feature, modifying
the structure of those vesicles in order to improve the delivery to target tissues: for instance, it is
possible to improve the blood circulation of EVs coating them with polyethylene glycol, or increasing
the expression of CD47 on the vesicle surface, or using specific residues (like the C1C2 domain of
Lactadherin) in order to conjugate specific antibodies on the EV surface, switching and driving the
specificity of the complex [171,193,194].
An emerging drug delivery strategy, based on nanoparticles, that has demonstrated great potential
in the treatment of different diseases and in regenerative medicine [135], is to create a hybrid carrier
between exosomes and liposomes, in order to combine the features that may increase the effectiveness
of anticancer therapies. These exciting new approaches consist of membrane fusion methods and have
the aim to combine the high yield and high drug-loading capacity of liposomes with the EVs’ intrinsic
properties, such as low immunogenicity, stability in circulation and high efficiency in target reaching
and in tissue retention [195–197]. The freeze–thaw method has been used to induce the mixing of
liposome and exosome membranes, which have been embedded with a specific membrane protein.
This has determined the enhancing of the delivery function of the exosomes by changing the lipid
composition or the properties of the exosome by membrane fusion [179,198]. This process seems to be
exploiting the biocompatibility of EVs, allowing the camouflage of liposomes by enriching their lipid
bilayer and inner compartment with biogenic molecules and on the other side, improve the EV drug
loading, proper of liposomes [170,198]. More recently, the functionalization of exosomes, to increase
their ability to deliver various contents into cells, has been successfully tested using nanogel systems
that ensure their effective delivery in a functionally intact state [199]. Other interesting technologies
have developed artificial nanovesicles, with features resembling those of EVs membrane and obtained
from broken cells [200,201]. Despite the exciting potential of engineered EVs as drug delivery systems,
the feasibility, and scalability of EVs and EVs-like systems are strongly dependent on some aspects that
need to be addressed to accelerate the translation into the clinic. The issues that must be defined include
the characteristic of the EVs source that entails the question of effectiveness and biocompatibility.
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Important are the isolation, storage and quality control procedures of EVs that affect the use of clinically
relevant doses and EVs-based therapy safety. Moreover, ethical issues are noteworthy.
Considering the growing interest and the breakthrough data that are continuously provided in
the field of EVs-based therapy, much progress is being taken to develop standardized protocols and
to establish efficacy and biosecurity criteria, to the aim to translate this platform into reality to treat
diseases like cancer.
4. Malignant Pleural Mesothelioma: The Lack of Efficient Therapeutic Strategies and Possible
Drug Delivery Strategies
Malignant mesothelioma (MM) is an insidious neoplasm arising from mesothelial surfaces such
as pleura and peritoneal cavities, pericardium and tunica vaginalis. The distribution of the tumor may
involve lining cells in a continuous manner. Among all different subtypes of MM, MPM is the most
common one [202–206].
MPM is an aggressive, rare tumor, with increasing incidence and poor prognosis. The massive use
of asbestos after the Second World War exposed a significant number of people to asbestos, dramatically
increasing the risk of developing MPM in 1960. Although the use of asbestos was significantly reduced
or abandoned in the western world in the 1980s, because of the long latency between the exposure
to the contaminant agent (asbestos) and the onset of the disease (from 15 to 60 years), mortality due
to MPM continued to rise [207–210]. The global incidence of MPM is uncertain: this is due to a poor
compatibility of databases from different countries, and few international data is available [208]. It is
estimated that every year around 43,000 people die due to this tumor [202,208]. In Italy, according to
epidemiological studies, MM represents 0.4% of the total amount of tumors diagnosed in men and 0.2%
in women (AIRTUM). As mentioned before, in the last ten years there has been a significant increase in
the diagnosis of this rare neoplasia, also due to the mean latency of the tumor of 44.6 years in 2544
cases diagnosed in the period from 1993 to 2001 [202,208].
A macroscopic observation is not enough for diagnosing MPM, as it is not always easy to
distinguish between a benign pleural lesion and a malignant one. Certainly, the best way to evaluate
the malignancy is to analyze the presence of tumor invasion. Furthermore, some MPM patients
are not eligible for pleural biopsy, and diagnosis must be conducted on pleural effusions (PE) [211].
Considering the above, finding affordable biomarkers that can ease the recognition of malignant
subtypes seems to be necessary. Unfortunately, current methods of detection, based on the most
common alteration documented on MPM, lack in reliability and are generally not recommended.
In fact, it is possible to say that currently there are no standardized diagnostic methods based on the
most common genetic MPM’s alterations. Nevertheless, a transversal analysis conducted by Bruno
R. et al. [212] has investigated the possibility to find new suitable biomarkers: first, the classical
approach, involving standard immunohistochemical biomarkers such as glucose transporter 1, p53,
desmin, epithelial membrane antigens and insulin-like growth factor mRNA binding proteins [211–215],
has been combined with soluble PE biomarkers, then it has been evaluated through ELISA assay
(mesotelin and fibulin-3). They have also evaluated new emerging biomarkers, recently introduced in
the clinical practice (BAP1, breast cancer associated protein 1, through immunohistochemistry and
p16 through, fluorescence in situ hybridization) [216]. Despite promising results, Bruno’s team has
demonstrated that none of the tissues and soluble markers are highly sensitive enough to distinguish
benign from malign pleural lesions. Only BAP1 and p16 showed a high specificity in discerning pleural
lesions, both in PEs and tissues. Those two markers, BAP1 and p16, result exclusively unexpressed or
deleted only in MPM. Considering that BAP1 and p16 are not deleted in all MPMs and their sensitivity
can variate between 43% and 93% for p16 and 61–67% for BAP1, negative results can sometimes be
inconsistent in order to exclude the malignancy [204,217,218]. Therefore, these markers may be not
specific to MPM, but may aid diagnosis and may have prognostic significance [216–218].
Another important field of increasing interest concerns the link between MPM and EVs, especially
exosomes. Currently, the role that exosomes, secreted by MPM, exert in tumoral progression, and their
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effector functions are increasingly being investigated. The analysis of samples of PE obtained
from various patients proved to be enriched by EVs secreted by the tumor itself and, in particular,
by exosomes [70,219,220]. However, currently, there are very few works in the literature about
the function of exosomes secreted by the MPM. In order to identify the function and catalog the
mesothelial-derived EVs, a close proteomic analysis was carried out on MM-derived exosomes. From an
initial pool of 2178 proteins present in the exosomal isolate, all proteins common to all exosomes or
proteins involved in their biogenesis (such as ESCRT or tetraspanins) have been excluded. Following
this, it was possible to underline several proteins that constitute a sort of molecular “fingerprint”
of MPM: the list of potential candidates as mesothelioma biomarkers includes, but is not limited
to, Piruvate Kinase, Annexin A1 and A2, Heat Shock Cognate 71, Heat Shock Protein 90, Alpha
Enolase, glucose6-phosphate1-dehydrogenase and 5 tubulin isotypes (such as TUBB4A, Q8IWP6 and
B3KPS3) [219].
These and other potential candidates constitute the so-called “mesothelioma exosomal signature”,
a potential pool of 570 proteins that can be used as markers for early and minimally invasive diagnoses,
or as a basis for deepening the signaling mediated by the MPM-derived exosomes, and the way in
which the secreted EVs influence the tumor microenvironment [219].
Anyway, as for the other tumor types, some specific functions mediated by the active secretion
of exosomes by MPM have been analyzed and reported in the literature. In fact, it has been shown
how MPM-derived-exosomes are involved in the formation of “tunneling nanotubes”, which are
actin-based cellular extensions that act as channels for the transport of cellular material, in order to
implement cell–cell communication [221]. In addition, MPM-derived exosomes also mediate immune
evasion through the downregulation of the Natural Killer (NK) group 2 member D receptor, which
is normally involved in the killing mediated by NK cells and by CD8+ T cells [222]. Finally, it has
been observed how, through the exosome-mediated expression of CD39 and CD73, MPM can induce
the extracellular expression of adenosine that, in turn, behaves as an immunomodulator exerting an
anti-inflammatory action by suppressing the T-cell mediated response [223].
5. Future Perspective: The Challenge in the Exploitation of EVs in MPM Therapy
Concerning treatments, the handling and management of MPM therapies are a challenge for
clinicians. First-line approaches include surgical intervention, chemotherapy or both of them. However,
none of the actual standard therapies approved could be considered as an ultimate cure, but more as
a palliative treatment. Moreover, currently, a standardized second-line therapy, meant as a different
and effective treatment, does not exist and the overall survival rate after a two year follow-up remains
poor [224,225].
In the oncological field, lines of treatment are dramatically important. These refer to different
approaches to handle the cancer at different times. First line treatment is the first approach indicated
by international guidelines. Other lines of treatment are usually exploited to treat tumors in which the
first line approach does not work, side effects of the first line are not well-tolerated by the patient or
new approaches seem to be more effective [226].
Therefore, the importance of new strategies that may lead to a more efficient and proficient
handling of MPM is clear.
Several trials have been performed with the aim of increasing MPM treatment options for patients
that respond negatively to the first line treatment.
An interesting ongoing clinical trial concerns the possibility of using pegylated phospholipid
vesicles as a carrier for doxorubicin [227]. This study is proposed as a possible first-line treatment
for the handling of MPM, by implementing the uptake of doxorubicin directly in the tumor site,
consequently reducing the side effects of traditional systemic therapy, with acceptable toxicity values
that improve the patient’s quality of life [227].
Another phase II study, conducted by Szlosarek et al., concerns the use of pegylated arginine
deaminase (ADI-PEG20) [228]. In fact, preclinical studies demonstrate how arginosuccinate synthetase
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1 (ASS1) enzyme deficient tumors are sensitive to arginine deprivation, leading to cell death. The trial
showed that the progression free-survival (PFS) of patients treated with the compound ADI-PEG20
increased compared to the control group (15.7 months in the ADI-PEG20 group versus 12.1 months of
PFS in the control group) [228].
Promising results also come from the use of a humanized anti-EGFR (epidermal growth factor
receptor) antibody, Nimotuximab (h-R3) [61]. In the study in question, the researchers wanted to
evaluate antibody biodistribution, uptake on the tumor site and binding affinity for EGFR. The study
was conducted in vivo on MPM xenograft models, radiolabeling the antibody with Gallium-67,
demonstrating a remarkable uptake of the antibody-radiolabeled complex at the tumor site [61].
Concerning the above-mentioned possible therapeutic tools in drug delivery, it might be tempting
to consider EVs, and exosomes more specifically, as a potential therapeutic tool in the handling of MPM.
Nevertheless, the small amount of works in the literature leads us to further investigate the connection
between EVs and MPM. In this regard, once the effective relevance of the production of exosomes by
the MPM has been assessed, it would be interesting to discover whether it is possible, and if so how,
to exploit this system of cancer communication in order to deliver exogenous molecules, possibly with
therapeutic functions, using the natural tumor network to attack itself with its own messengers.
The idea we want to propose is the exploitation of EVs isolated from primary cell cultures of
MPM, in order to be able to modify them through post-loading techniques. In this way, even though
the isolation efficiency might be lower if compared to therapies with recombinant proteins (>5 g/L of
culture medium) [171,229], the final product would be far more representative of the actual secretome
of the MPM. This would allow an expression of surface receptors of tumoral exosomes closer to the
physiological one; it would also theoretically allow a more efficient drug loading, through post-loading
techniques, and drug delivery.
Among other things, exosome surface proteins define their tropism, and today the pivotal role of
EVs on tumor signaling is largely confirmed [230].
Due to the relative simplicity and low cost of EV manipulation techniques, they represent a
potentially suitable model of DDS. The prospect of attacking the tumor by exploiting its own messengers
is not only fascinating from a scientific point of view, but also clinically remarkable: the biocompatibility
of a biopharmaceutical like this, based on a loading into the vesicles of a drug, it would be complete.
In addition, unlike the strategies adopted in other drug delivery models, in which specificity is
entrusted to a single molecule present on the surface of the target cell (e.g., monoclonal antibodies and
peptide-based nanocarriers), EVs can rely on a much more layered and complex vehiculation system.
Of course, a careful evaluation of the tumor microenvironment, the choice of an ad hoc delivery system
and the electric charge of the nanocarrier have to be taken into account.
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